AzTrials
AzTrials

Child ObesityNCT03870984

Efficacy of Nuts in Obese Children.

A study testing wNUTS, low-caloric diet plus nuts and w/oNUTS, low-caloric diet without nuts in people with Child Obesity, run by Universita di Verona at 1 site in Italy.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Obesity is a problem of ever-growing importance, especially in industrialized countries, both in adults and in the pediatric population. Children and obese adolescents, like adults, have an increased risk, compared with normal-weight peers, to develop metabolic syndrome and atherosclerotic disease, pathophysiological… Read more about this study

Who is it for?
Ages 6 to 17 yearsHealthy volunteers can take part
Conditions the study is for
Child Obesity
What is being tested?
wNUTS, low-caloric diet plus nuts and w/oNUTS, low-caloric diet without nuts
Could I receive a placebo?
No, everyone receives an active treatment
How many people
8 participants
Where
1 siteItaly
Study dates
19 Mar 2019to 18 May 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 17 years
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • obese subjects (BMI ≥ 95th percentile for age and sex; reference tables for WHO BMI);
  • Aged between 6 and 17 years;
  • Signature applied in the informed consent by both parents and consent of the child

Who cannot join

  • chronic liver diseases (hepatitis, cirrhosis).
  • Chronic renal failure (serum creatinine> 1.2 mg / dL).
  • Malignancies.
  • Diabetes (fasting blood glucose ≥ 126 mg / dl or therapy with oral hypoglycemic drugs or insulin).
  • cholesterol-lowering or antihypertensive terapy.
  • Notes allergies to nuts or hazelnuts or food intolerance to nuts and/or hazelnuts.
  • Treatment of less than 6 weeks with any medication which can interfere with fecal microbiota (particularly antibiotics or laxatives).

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • AOUI Verona

    Verona, VR, 37134

Other trials in Italy

About this study

Official title: Efficacy of Walnuts and Hazelnuts on the Modification of the Lipid Content of Erythrocyte Membranes in Obese Children. A Randomised Controlled Trial.

Obesity is a problem of ever-growing importance, especially in industrialized countries, both in adults and in the pediatric population. Children and obese adolescents, like adults, have an increased risk, compared with normal-weight peers, to develop metabolic syndrome and atherosclerotic disease, pathophysiological basis of cardiovascular events. Alteration of the elastic properties of the arteries has been described previously in obese children and adolescents and is considered an initial marker of atherosclerotic vascular damage. The determination of the indices of arterial stiffness (PWV, Pulse Wave Velocity; AI, Augmentation Index, SI, Stiffness Index) is possible through techniques currently used for the determination of vascular function even in children.

Nuts and hazelnuts are rich in potentially beneficial substances including unsaturated fatty acids, especially omega-6 (present in both) and omega-3 (present only in nuts), Several clinical trials have already shown in adults a potential beneficial effect of the addition of different types of nuts (walnuts, hazelnuts, cashews, pistachios, etc.) on the characteristics of the metabolic syndrome also through their possible antioxidant effect and vasoactive. In children, some epidemiological studies have associated with a higher consumption of nuts reduced risk of hypertension, dyslipidemia, obesity and fasting glucose. The study will be conducted with a randomized design with two arms in parallel with blinded operator. The main objective of this study is to assess the efficacy of 15 grams of nuts and 15 grams of nuts a day in addition to a low calorie diet on the content of erythrocyte membranes of alpha-linolenic acid three months after the beginning of the trial in a group of obese children. Secondary objectives are to evaluate the efficacy of walnuts and hazelnuts in improving the systolic and/or diastolic blood pressure values, lipid profile, glucose and fasting insulin, vascular function.

Read the detailed description

Obesity is a problem of ever-growing importance, especially in industrialized countries, widespread both in adults and in the pediatric population.

Children and obese adolescents, like adults, have an increased risk, compared with normal-weight peers, to develop high blood pressure, insulin resistance, diabetes, hyperlipidemia, fatty liver disease and the resulting long-term complications. This cluster of metabolic and hemodynamic risk factors, which is known as metabolic syndrome, greatly increases the risk of cardiovascular events in adults. Cardiovascular disease is the leading cause of mortality and morbidity in developed countries and are becoming even in developing countries. Atherosclerotic disease is the pathophysiological basis of cardiovascular events. Atherosclerosis is a multifactorial disease whose early stages of subclinical damage are documented much earlier in cardiovascular events with non-invasive tests. The determination of the indices of arterial stiffness (PWV, Pulse Wave Velocity; AI, Augmentation Index, SI, Stiffness Index) is possible through techniques currently used for the determination of vascular function even in children. The alteration of the elastic properties of the arteries has been described previously in obese children and adolescents and is considered initial marker atherosclerotic vascular damage. Fats particularly saturated fats, without adequate intake of polyunsaturated fat, may facilitate the development of obesity.

The consumption of some specific foods including dried fruit (in a broad sense including walnuts, hazelnuts, almonds, cashews, etc.) within a reduced calorie diet is considered to be a promising approach in the prevention and care of the different components of the metabolic syndrome. The nuts and hazelnuts are rich in potentially beneficial substances including unsaturated fatty acids, especially omega-6 (present in both) and omega-3 (present only in nuts), L-arginine, fiber, minerals, vitamin E, fitosetrols and polyphenols.

Several clinical trials have already shown in adults a potential beneficial effect of the addition of different types of nuts (walnuts, hazelnuts, cashews, pistachios, etc.) on the characteristics of the metabolic syndrome also through their possible antioxidant and vasoactive effect .

In children, some epidemiological studies have associated a higher consumption of nuts with reduced risk of hypertension, dyslipidemia, obesity and fasting glucose alteration.

Our group conducted a study in obese children observing an inverse relationship between omega-6 polyunsaturated fatty acids, contained in large amounts in walnuts, and certain features of metabolic syndrome, such as waist circumference, triglycerides, fasting insulin, systolic blood pressure of 24-hours, suggesting a possible beneficial effect. The project was financed by health ministry and included also the present Protocol ("Obesity, hypertension and subclinical vascular damage in children: the role of dietary factors and lipid mediators. An epidemiological and translational study. "Project Code: GR-2011-02349630).

From arachidonic acid, the main omega-6 type polyunsaturated fatty acids (PUFA), certain metabolites are produced via cytochrome P450 which have vasoactive and natriuretic effect: 20-Hydroxyeicosatetraenoic acid (20-HETE), the epoxyeicosatrienoic acids (EETs) and dihydroxyeicosatrienoic acids (DHETs). From numerous studies in animal models and some human studies, it is known that these metabolites via cytochrome P450 may be involved both in the homeostasis of blood pressure pressure and in the development of hypertension. In particular, plasmatic 20-HETE has a vasoconstrictor effect while EETs are vasodilators; both exert renal natriuretic effect. Our study intends to verify if in a group of obese children, a low-calorie diet that contains a portion of walnuts and hazelnuts, can change the content of polyunsaturated fatty acids in erythrocyte membranes, particularly alpha-linolenic acid. This could result in possible beneficial effects on the characteristics of the metabolic syndrome in obese children, like an improvement of waist circumference, blood pressure, HDL cholesterol, triglycerides and blood sugar. Our study also intends to acquire information on the effect of the addition of walnuts and hazelnuts and the metabolites of polyunsaturated fatty acids omega-3 and omega-6 metabolized by cytochrome P450 that derives from these nuts in change vessel elasticity.

  1. STUDY DESIGN The study will be conducted with a randomized design (two arms in parallel with blinded operator). Doctors in charge of vascular measurements and laboratory technicians will not know which of the two groups analyzed will only have taken the low-calorie diet and who will have assumed the low-calorie diet with walnuts and hazelnuts.
  2. PURPOSE OF THE STUDY

The main objective of this study is to assess the efficacy of 15 grams of nuts and 15 grams of nuts a day in addition to a low calorie diet, in modifying the content of of alpha-linolenic acid in erythrocyte membranes evalutated three months after the beginning of the assumption in a group of obese children.

Secondary objectives are:

To evaluate the efficacy of walnuts and hazelnuts in improving in obese children:

  • the systolic and/or diastolic blood pressure values;
  • metabolic disorders (in particular of the lipid profile: LDL, HDL, triglycerides, and glucose: glucose and fasting insulin);
  • vascular function measured by tonometry (PWV and PWA), and ultrasonography (carotid distensibility).
  • the modifications of the profile of eicosanoids via CYP450 in plasma and urine

To evaluate:

  • the relationship between intake of nuts and hazelnuts, fatty acid profile of erythrocyte membranes and eicosanoids via CYP450, the components of the metabolic syndrome including the blood pressure and vascular elasticity.
Conditions
Child Obesity
Being tested
wNUTS, low-caloric diet plus nuts, w/oNUTS, low-caloric diet without nuts
Keywords
obesity, children, nuts,
Medical subject headings
Pediatric Obesity, Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • wNUTS, low-caloric diet plus nutsDietary supplement

    15g of nuts and 15g of hazelnuts in association with low caloric diet

  • w/oNUTS, low-caloric diet without nutsOther

    low caloric diet

Study groups in NCT03870984
Study groupRoleWhat they receive
wNUTS, low-caloric diet plus nutsExperimentallow-caloric diet personalized on single children's requirements plus nuts (15g hazelnuts+15g nuts without shell) for 3 months.
Receives: Dietary Supplement: wNUTS, low-caloric diet plus nuts; Other: w/oNUTS, low-caloric diet without nuts
w/oNUTS, low-caloric diet without nutsOtherlow-caloric diet personalized on single children's requirements plus nuts (15g hazelnuts+15g nuts without shell) for 3 months.
Receives: Other: w/oNUTS, low-caloric diet without nuts

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. ALA change

    Primary outcome is to compare percentage of fatty acids in erythrocyte membranes (in particular alpha-linolenic acid, ALA) with the content of other membrane-bound fatty acids. It will be compared in the two groups the ALA delta (delta%) between measurement at baseline compared to post-treatment (ie, after 3 months of treatment).

    Measured: baseline compared to post-treatment (ie, after 3 months of treatment)

Secondary outcomes (19)
  1. LA change

    to compare percentage of fatty acids in erythrocyte membranes (in particular linoleic acid, LA) with the content of other membrane-bound fatty acids. It will be compared in the two groups the ALA delta (delta%) between measurement at baseline compared to post-treatment (ie, after 3 months of treatment).

    Measured: baseline compared to post-treatment (ie, after 3 months of treatment)

  2. ABPM change

    To compare ambulatory blood pressure (mmHg) measured by validated devices (A\&D TM-2430; in the week preceding the beginning of the assumption of diet plus or minus nuts/hazelnuts) and after 3 months from randomization in the two arms.

    Measured: baseline compared to post-treatment (ie, after 3 months of treatment)

  3. OFFICE BLOOD PRESSURE change

    To compare mean arterial pressure obtained during the medical examination (mmHg) by oscillometric validated device in children (Omron 705 IT; average of three measurements) prior to randomization and after 3 months of diet intake plus or minus nuts/hazelnuts.

    Measured: baseline compared to post-treatment (ie, after 3 months of treatment)

  4. HDL-cholesterol change

    To compare HDL-cholesterol

    Measured: baseline compared to post-treatment (ie, after 3 months of treatment)

  5. triglycerides change

    To compare triglycerides

    Measured: baseline compared to post-treatment (ie, after 3 months of treatment)

  6. glucose change

    To compare plasma glucose

    Measured: baseline compared to post-treatment (ie, after 3 months of treatment)

  7. WAIST CIRCUMFERENCE change

    To compare waist circumference change in the 2 arms prior to randomization and after 3 months of diet intake plus or minus nuts/hazelnuts.

    Measured: baseline compared to post-treatment (ie, after 3 months of treatment)

  8. WEIGHT change

    To compare weight change in the 2 arms prior to randomization and after 3 months of diet intake plus or minus nuts/hazelnuts.

    Measured: baseline compared to post-treatment (ie, after 3 months of treatment)

  9. PWA (Augmentation Index; AIx) change

    To compare AIx change as measured by pulse wave analysis (PWA) by SphygmoCor XCEL and in the 2 arms prior to randomization and after 3 months of diet intake plus or minus nuts/hazelnuts.

    Measured: baseline compared to post-treatment (ie, after 3 months of treatment)

  10. cfPWV change

    To compare carotid femoral pulse wave velocity (PWV) change measured by tonometer (SphygmoCor XCEL) in the 2 arms prior to randomization and after 3 months of diet intake plus or minus nuts/hazelnuts.

    Measured: baseline compared to post-treatment (ie, after 3 months of treatment)

  11. carotid distensibility (cDC) change

    To compare cDC change measured by ultrasound in the 2 arms prior to randomization and after 3 months of diet intake plus or minus nuts/hazelnuts.

    Measured: baseline compared to post-treatment (ie, after 3 months of treatment)

  12. plasma EETs change

    To compare plasma epoxyeicosatrienoic acids, metabolites of arachidonic acid vis CYP450

    Measured: baseline compared to post-treatment (ie, after 3 months of treatment)

  13. plasma DHETs change

    To compare plasma dihydroxyeicosatrienoic acids, metabolites of EETs via sEH

    Measured: baseline compared to post-treatment (ie, after 3 months of treatment)

  14. urine DHETs change

    To compare urine dihydroxyeicosatrienoic acids, metabolites of EETs via sEH

    Measured: baseline compared to post-treatment (ie, after 3 months of treatment)

  15. plasma 20-HETE change

    To compare plasma 20-hydroxyeicosatetraenoic acids, metabolites of arachidonic acid via CYP450

    Measured: baseline compared to post-treatment (ie, after 3 months of treatment)

  16. urine 20-HETE change

    To compare urine 20-hydroxyeicosatetraenoic acids, metabolites of arachidonic acid via CYP450

    Measured: baseline compared to post-treatment (ie, after 3 months of treatment)

  17. plasma EEQs change

    To compare plasma epoxyeicosatetraenoic acids, metabolites of eicosapentaenoic acid via CYP450

    Measured: baseline compared to post-treatment (ie, after 3 months of treatment)

  18. plasma EDPs change

    To compare plasma epoxydocosapentaenoic acids, metabolites of docosahexaenoic acid via CYP450

    Measured: baseline compared to post-treatment (ie, after 3 months of treatment)

  19. MICROBIOTA change

    To compare profile of the faecal microbiota by metagenomic of the gene sequences coding for the 16S rRNA prior to randomization and after 3 months of diet intake plus or minus nuts/hazelnuts.

    Measured: baseline compared to post-treatment (ie, after 3 months of treatment)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Mar 2019
  2. Study start19 Mar 2019
  3. Primary completion18 May 2022
  4. Study completion18 May 2022

Why it stopped: Lack of recruitment

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomized design. Two arms in parallel with blinded operator.
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
8 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03870984
Sponsor's protocol ID
VRINoci
Status last verified
May 2022
First submitted
6 Mar 2019
Last updated
25 May 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing wNUTS, low-caloric diet plus nuts and w/oNUTS, low-caloric diet without nuts in people with Child Obesity, run by Universita di Verona at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 25 May 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Lack of recruitment). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

ALA change (time frame: baseline compared to post-treatment (ie, after 3 months of treatment)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 May 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in